Sign In
Buy KALA
$0.699
-0.0071 (-1.01%)
At Close: Nov 17, 2025
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
12:21pm, Wednesday, 08'th Oct 2025
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
Kala Bio downgraded to Neutral from Outperform at Mizuho
09:32am, Tuesday, 30'th Sep 2025
Mizuho downgraded Kala Bio to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday's negative Phase 2 results for the company's lead asset KPI-012 for the down
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?
12:00pm, Monday, 29'th Sep 2025
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
10:55am, Wednesday, 13'th Aug 2025
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Kala Bio (KALA) Q2 Loss Widens 15%
08:18am, Friday, 08'th Aug 2025
Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Friday, 08'th Aug 2025
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 mill
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 06'th Aug 2025
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
12:56pm, Friday, 25'th Jul 2025
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on p
KALA BIO to Present at Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t
KALA BIO Announces Chief Executive Officer Transition
08:00am, Wednesday, 12'th Feb 2025
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO Announces $10,750,000 Private Placement
08:00am, Monday, 30'th Dec 2024
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:57am, Monday, 16'th Dec 2024
KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
08:00am, Wednesday, 27'th Nov 2024
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
01:05pm, Wednesday, 09'th Oct 2024
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
